2007
Cutaneous T-cell lymphoma: Biologic targets for therapy
Choi J, Foss F. Cutaneous T-cell lymphoma: Biologic targets for therapy. Current Hematologic Malignancy Reports 2007, 2: 272-277. PMID: 20425380, DOI: 10.1007/s11899-007-0037-8.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic AgentsApoptosisCD4 AntigensClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsDrug DesignEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansImmunologic FactorsImmunotherapyInterferon-gammaInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsPhotopheresisRecombinant Fusion ProteinsSkin NeoplasmsT-Lymphocyte SubsetsTumor EscapeConceptsCutaneous T-cell lymphomaReceptor-dependent signaling pathwaysEpigenetic changesSignaling pathwaysClonal populationsSkin-homing lymphocytesT-cell lymphomaT cell activationPersistence of tumorHost immune systemCTCL cellsCancer immunosurveillanceImmune cellsLangerhans cellsCytotoxic phenotypeDisease pathogenesisBiologic targetsImmune systemCellsTherapyDiseasePhenotypePathwayImmunosurveillanceActivation
2003
Interleukin-2 receptor–directed therapies for cutaneous lymphomas
Foss FM, Waldmann TA. Interleukin-2 receptor–directed therapies for cutaneous lymphomas. Hematology/Oncology Clinics Of North America 2003, 17: 1449-1458. PMID: 14710895, DOI: 10.1016/s0889-8588(03)00110-2.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalClinical Trials as TopicDiphtheria ToxinDrug Delivery SystemsGene Expression Regulation, NeoplasticHumansImmunoconjugatesImmunotherapyImmunotoxinsInterleukin-2Lymphoma, T-Cell, CutaneousNeoplasm ProteinsProtein IsoformsProtein SubunitsReceptors, Interleukin-2Recombinant Fusion ProteinsRetinoidsSkin NeoplasmsConceptsT-cell lymphomaIL-2RIL-2/IL-2R systemPeripheral T-cell lymphomaAnaplastic large cell lymphomaNatural killer lymphomaReceptor-directed therapyIL-2R systemIL-2 receptorLarge cell lymphomaRational therapeutic strategiesIL-2R subunitsCutaneous lymphomasSpecific immunotherapyIL-2Cell lymphomaTherapeutic strategiesLymphomaHumanized antibodyCTCLBeta-emitting radionuclidesAntibodiesImmunotherapyTherapyAgentsNovel agents for cutaneous T-cell lymphoma
Kuzel TM, Junghans R, Foss FM. Novel agents for cutaneous T-cell lymphoma. Hematology/Oncology Clinics Of North America 2003, 17: 1459-1466. PMID: 14710896, DOI: 10.1016/s0889-8588(03)00112-6.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntineoplastic AgentsDrug Delivery SystemsDrug DesignHumansLymphoma, T-Cell, CutaneousMiceMice, SCIDSkin NeoplasmsOverview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches
Foss F. Overview of Cutaneous T-Cell Lymphoma: Prognostic Factors and Novel Therapeutic Approaches. Leukemia & Lymphoma 2003, 44: s55-s61. PMID: 15202526, DOI: 10.1080/10428190310001623757.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsDrug Delivery SystemsHumansLymphoma, T-Cell, CutaneousPrognosisTreatment OutcomeConceptsCutaneous T-cell lymphomaT-cell lymphomaNovel agentsTherapeutic approachesAcute T-cell leukemia/lymphomaAdvanced refractory cutaneous T cell lymphomasEarly-stage cutaneous T-cell lymphomaMycosis fungoides/Sézary syndromeRefractory cutaneous T-cell lymphomaPeripheral T-cell lymphomaAllogeneic stem cell therapyT-cell leukemia/lymphomaDemonstrated survival benefitYear of diagnosisAdvanced-stage patientsCytokine receptor antagonistsProbability of progressionNovel therapeutic approachesLeukemia/lymphomaNew therapeutic approachesNF-kappaB inhibitorHistone deacetylase inhibitorsStem cell therapyCytotoxic regimensExtracutaneous disease